Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Carcinoma|Recurrent Breast Carcinoma|Stage IV Breast Cancer
Interventions: BIOLOGICAL: Bevacizumab|DRUG: Carboplatin|DRUG: Paclitaxel|OTHER: Placebo|BIOLOGICAL: Trastuzumab
Sponsor: National Cancer Institute (NCI)